Dexamethasone + Neomycin + Polymyxin B
21 adverse event reports submitted to the FDA
Active Ingredients
Administration Routes
Species Affected
Most Affected Breeds
Most Reported Reactions
Outcome Breakdown
Data Summary
| Metric | Value |
|---|---|
| Total adverse event reports | 21 |
| Reports involving death | 0 |
| Case-fatality rate (reported events) | 0.0% |
| Distinct species in reports | 2 |
| Distinct breeds in reports | 16 |
| Distinct reactions reported | 20 |
| Active ingredients on file | 4 |
Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.
Dexamethasone + Neomycin + Polymyxin B Adverse Event Insights
The FDA Center for Veterinary Medicine database currently holds 21 adverse event reports referencing Dexamethasone + Neomycin + Polymyxin B, including 0 reports in which the animal died — a 0.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredients on file: Dexamethasone, Dexamethasone + Neomycin + Polymyxin B, Neomycin, Polymyxin B. Reported administration routes include Unknown, Intraocular, Ophthalmic, Auricular (Otic). These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.
The species most frequently named in Dexamethasone + Neomycin + Polymyxin B reports are Dog (18 reports), Cat (3 reports), with Dog accounting for the largest share. Within those species, Shih Tzu (3), Bulldog - French (2), Chihuahua (2) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.
The most commonly reported clinical signs associated with Dexamethasone + Neomycin + Polymyxin B are Corneal ulcer (6), Eye disorder NOS (for Photophobia see neurological) (5), Ocular discharge (5), Squinting (4). Of the 21 reports with a coded outcome, Ongoing is the leading category at 42.9%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Dexamethasone + Neomycin + Polymyxin B.
Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates
Read our methodology — how this data is sourced, computed, and verified.